Talisman’s Focus Back

Talisman Therapeutics has built a world-class series of human stem cell models of Alzheimer’s disease, which are the basis of our proprietary drug development system. These circumvent known problems with existing animal-based models of Alzheimer’s disease. Talisman Therapeutics’ core intellectual property is based on the work of founding scientist Dr Rick Livesey at the Gurdon Institute, Cambridge.

Our technology is unique because human stem cells are used to produce disease-relevant neurons that replicate the different stages of the Alzheimer’s disease process, thereby offering several different phases of the disease to target therapeutically. By using human stem cell-based models early in the drug development process, we identify pathways that have much greater relevance to the disease process in the part of the human brain affected by the disease.